These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 21316152)
1. Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic. Hough LB; Nalwalk JW; Yang J; Conroy JL; VanAlstine MA; Yang W; Gargano J; Shan Z; Zhang SZ; Wentland MP; Phillips JG; Knapp BI; Bidlack JM; Zuiderveld OP; Leurs R; Ding X Pain; 2011 Apr; 152(4):878-887. PubMed ID: 21316152 [TBL] [Abstract][Full Text] [Related]
2. Physiological basis for inhibition of morphine and improgan antinociception by CC12, a P450 epoxygenase inhibitor. Heinricher MM; Maire JJ; Lee D; Nalwalk JW; Hough LB J Neurophysiol; 2010 Dec; 104(6):3222-30. PubMed ID: 20926616 [TBL] [Abstract][Full Text] [Related]
3. CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist. Hough LB; Nalwalk JW; Phillips JG; Kern B; Shan Z; Wentland MP; de Esch IJ; Janssen E; Barr T; Stadel R Neuropharmacology; 2007 Apr; 52(5):1244-55. PubMed ID: 17336343 [TBL] [Abstract][Full Text] [Related]
4. Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic. Hough LB; de Esch IJ; Janssen E; Phillips J; Svokos K; Kern B; Trachler J; Abood ME; Leurs R; Nalwalk JW Neuropharmacology; 2006 Sep; 51(3):447-56. PubMed ID: 16806300 [TBL] [Abstract][Full Text] [Related]
5. A role for spinal, but not supraspinal, alpha(2) adrenergic receptors in the actions of improgan, a powerful, non-opioid analgesic. Svokos K; Nalwalk JW; Leurs R; Menge WM; Timmerman H; Hough LB Brain Res; 2001 Dec; 923(1-2):12-9. PubMed ID: 11743967 [TBL] [Abstract][Full Text] [Related]
6. Antinociceptive, brain-penetrating derivatives related to improgan, a non-opioid analgesic. Hough LB; Nalwalk JW; Lu Q; Shan Z; Svokos K; Wentland MP; Montero MJ Eur J Pharmacol; 2005 Oct; 522(1-3):38-46. PubMed ID: 16216240 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors. Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266 [TBL] [Abstract][Full Text] [Related]
8. Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature. Salussolia CL; Nalwalk JW; Hough LB Brain Res; 2007 Jun; 1152():42-8. PubMed ID: 17433267 [TBL] [Abstract][Full Text] [Related]
9. Significance of cannabinoid CB1 receptors in improgan antinociception. Gehani NC; Nalwalk JW; Razdan RK; Martin BR; Sun X; Wentland M; Abood ME; Hough LB J Pain; 2007 Nov; 8(11):850-60. PubMed ID: 17644043 [TBL] [Abstract][Full Text] [Related]
11. Significance of GABAergic systems in the action of improgan, a non-opioid analgesic. Hough LB; Nalwalk JW; Leurs R; Menge WM; Timmerman H Life Sci; 2001 May; 68(24):2751-7. PubMed ID: 11400917 [TBL] [Abstract][Full Text] [Related]
12. Improgan antinociception does not require neuronal histamine or histamine receptors. Izadi Mobarakeh J; Nalwalk JW; Watanabe T; Sakurada S; Hoffman M; Leurs R; Timmerman H; Silos-Santiago I; Yanai K; Hough LB Brain Res; 2003 Jun; 974(1-2):146-52. PubMed ID: 12742632 [TBL] [Abstract][Full Text] [Related]
13. Absence of 5-HT3 and cholinergic mechanisms in improgan antinociception. Nalwalk JW; Svokos K; Leurs R; Hough LB Pharmacol Biochem Behav; 2005 Mar; 80(3):505-10. PubMed ID: 15740793 [TBL] [Abstract][Full Text] [Related]
14. Antinociceptive activity of derivatives of improgran and burimamide. Hough LB; Nalwalk JW; Leurs R; Menge WM; Timmerman H Pharmacol Biochem Behav; 2000 Jan; 65(1):61-6. PubMed ID: 10638637 [TBL] [Abstract][Full Text] [Related]